Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug application ... FDA approved the product for the treatment of neuropathic pain associated with ...

Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological ...

Research shows neuropathy can be more severe and more common in Black breast cancer patients, causing doctors to dial back ...

Living with a chronic pain condition can make everyday tasks more challenging. For some people in Southern Utah dealing with ...

Lorna Rothery spoke to a team at Mid Yorkshire Teaching Hospital about the risk factors for and prevention of diabetic foot ...

Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic ...

When you think of the YMCA, you might think of working out. But the "Y's" Thriver's Club is about more than making your ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

The Georgia Department of Public Health just announced some big changes in an effort to make things easier for medical marijuana users.